Top

Cardiovascular Intervention and Therapeutics

Published in:

01-01-2015 | Case Report

A case of successful percutaneous transluminal septal myocardial ablation for heart failure due to severe left ventricular outflow obstruction with Mönckeberg’s arteriosclerosis, manifested after aortic valvular replacement

Authors: Masafumi Kato, Masatoshi Miyahara, Hiroyuki Suzuki, Fumiya Uchida, Yoshiyuki Nishimura, Hideo Nishikawa

Published in: Cardiovascular Intervention and Therapeutics | Issue 1/2015

Abstract

Although percutaneous transluminal septal myocardial ablation (PTSMA) has been the established treatment of symptomatic patients with hypertrophic obstructive cardiomyopathy (HOCM), the efficacy for specific HOCM is not elucidated. We report a successful case of PTSMA for heart failure with severe left ventricular outflow tract (LVOT) obstruction due to sigmoid-shaped interventricular septum and diffuse left ventricular hypertrophy with Mönckeberg’s arteriosclerosis and aortic valvular stenosis. While the PTSMA relieved LVOT obstruction and symptoms in the acute phase, the modest recurrence was confirmed 6 months later, which is rare in the case of idiopathic HOCM. The possible mechanisms of LVOT obstruction and recurrence are discussed.

Elliott P, McKenna WJ. Hypertrophic cardiomyopathy. Lancet. 2004;363:1881–91.PubMedCrossRef

Maron BJ, Gottdiener JS, Epstein SE. Patterns and significance of distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy. A wide angle, two dimensional echocardiographic study of 125 patients. Am J Cardiol. 1981;48:418–28.PubMedCrossRef

Maron MS, Olivotto I, Betocchi S, Casey SA, Lesser JR, Maria A, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med. 2003;348:295–303.PubMedCrossRef

Maron BJ. Controversies in cardiovascular medicine. Surgical myectomy remains the primary treatment option for severely symptomatic patients with obstructive hypertrophic cardiomyopathy. Circulation. 2007;116:196–206.PubMedCrossRef

Rigopoulos AG, Seggewiss H. A decade of percutaneous septal ablation in hypertrophic cardiomyopathy. Circ J. 2011;75:28–37.PubMedCrossRef

Lachman AS, Spray TL, Kerwin DM, Shugoll GI, Roberts WC. Medial calcinosis of Mönckeberg. A review of the problem and a description of a patient with involvement of peripheral, visceral and coronary arteries. Am J Med. 1977;63:615–22.PubMedCrossRef

Kovacic JC, Moreno P, Nabel EG, Hachinski V, Fuster V. Cellular senescence, vascular disease, and aging part 2 of a 2-part review: clinical vascular disease in the elderly. Circulation. 2011;123:1900–10.PubMedCrossRef

Topol EJ, Traill TA, Fortuin NJ. Hypertensive hypertrophic cardiomyopathy of the elderly. N Engl J Med. 1985;312:277–83.PubMedCrossRef

Pearson AC, Gudipati CV, Labovitz AJ. Systolic and diastolic flow abnormalities in elderly patients with hypertensive hypertrophic cardiomyopathy. J Am Coll Cardiol. 1988;12:989–95.PubMedCrossRef

10.

Aurigemma G, Battista S, Orsinelli D, Sweeney A, Pape L, Cuenoud H. Abnormal left ventricular intracavitary flow acceleration in patients undergoing aortic valve replacement for aortic stenosis. A marker for high postoperative morbidity and mortality. Circulation. 1992;86:926–36.PubMedCrossRef

11.

Routledge T, Nashef SAM. Severe mitral systolic anterior motion complicating aortic valve replacement. Interact Cardiovasc Thorac Surg. 4;4:486–7.CrossRef

12.

Mönckeberg JG: Uber die heine mediaverkalkung der extremitätenarterien und ihr verhalten zur arteriosklerose. Virchows Arch [Pathol Anat].1903;171:141–167.CrossRef

13.

Lakkis NM, Nagueh SF, Dunn JK, Killip D, Spencer WH 3rd. Nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy: one-year follow-up. J Am Coll Cardiol. 2000;36:852–5.PubMedCrossRef

14.

Mazur W, Nagueh SF, Lakkis NM, Middleton KJ, Killip D, Roberts R, et al. Regression of left ventricular hypertrophy after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation. 2001;103:1492–6.PubMedCrossRef

15.

Seggewiss H, Gleichmann U, Faber L, Fassbender D, Schmidt HK, Strick S. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results and 3-month follow-up in 25 patients. J Am Coll Cardiol. 1998;31:252–8.PubMedCrossRef

16.

Faber L, Meissner A, Ziemssen P, Seggewiss H. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: long term follow up of the first series of 25 patients. Heart. 2000;83:326–31.PubMedCentralPubMedCrossRef

17.

Tsuchikane E, Takeda Y, Kobayashi T, Yachiku K, Nasu K, Kobayashi Y, et al. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy initial and follow-up results in the first 27 patients. Circ J. 2003;67:763–7.PubMedCrossRef

18.

van Dockum WG, Beek AM, ten Cate FJ, ten Berg JM, Bondarenko O, Götte MJ, et al. Early onset and progression of left ventricular remodeling after alcohol septal ablation in hypertrophic obstructive cardiomyopathy. Circulation. 2005;111:2503–8.PubMedCrossRef

19.

Veselka J, Duchonová R, Páleníckova J, Zemánek D, Tiserová M, Linhartová K, et al. Impact of ethanol dosing on the long-term outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy: a single-center prospective, and randomized study. Circ J. 2006;70:1550–2.PubMedCrossRef

20.

Geske JB, Sorajja P, Ommen SR, Nishimura RA. Left ventricular outflow tract gradient variability in hypertrophic cardiomyopathy. Clin Cardiol. 2009;32:397–402.PubMedCrossRef

21.

Geske JB, Sorajja P, Ommen SR, Nishimura RA. Variability of left ventricular outflow tract gradient during cardiac catheterization in patients with hypertrophic cardiomyopathy. JACC Cardiovasc Interv. 2011;4:704–9.PubMedCrossRef

Title: A case of successful percutaneous transluminal septal myocardial ablation for heart failure due to severe left ventricular outflow obstruction with Mönckeberg’s arteriosclerosis, manifested after aortic valvular replacement
Authors: Masafumi Kato
Masatoshi Miyahara
Hiroyuki Suzuki
Fumiya Uchida
Yoshiyuki Nishimura
Hideo Nishikawa
Publication date: 01-01-2015
Publisher: Springer Japan
Published in: Cardiovascular Intervention and Therapeutics / Issue 1/2015
Print ISSN: 1868-4300
Electronic ISSN: 1868-4297
DOI: https://doi.org/10.1007/s12928-014-0252-x

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

At a glance: The STEP trials

Springer Medicine

A case of successful percutaneous transluminal septal myocardial ablation for heart failure due to severe left ventricular outflow obstruction with Mönckeberg’s arteriosclerosis, manifested after aortic valvular replacement

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2015

A successful treatment for a lesion of chronic total occlusion with contralateral angiography in a single radial access

Pop goes the balloon: a cautionary tale in transaortic intervention

Worsening late-acquired incomplete stent apposition after sirolimus-eluting stent implantation for a chronic total occlusion lesion

Failure of a balloon to deflate during post dilatation in a coronary artery

Modification of treatment strategy after FFR measurement: CVIT-DEFER registry

Long-term clinical and angiographic outcomes after sirolimus- and paclitaxel-eluting stent placement following rotablation for severely calcified lesions: a retrospective nonrandomized study

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page